Proteinase 3 as a marker of clinical severity in bronchiectasis: Data from the EMBARC-BRIDGE study
Emma Johnson(University of North Carolina at Chapel Hill), James D. Chalmers(University of Dundee), Josje Altenburg(Amsterdam University Medical Centers), Michal Shteinberg(Carmel Medical Center), Holly R. Keir(University of Dundee), Michael R. Loebinger(Royal Brompton Hospital), Charles Haworth(Papworth Hospital NHS Foundation Trust), Felix C. Ringshausen(Medizinische Hochschule Hannover), Raja Dhar(Fortis Hospital), Katerina Dimakou(Sotiria General Hospital), Pieter Goeminne(Vlaamse Vereniging voor Obstetrie en Gynaecolo), Erin Cant(University of Dundee), Natalie Lorent(KU Leuven), Sanjay H. Chotirmall(Translational Research Institute), Tobias Welte(Medizinische Hochschule Hannover), Amelia Shoemark(University of Dundee), Anthony De Soyza(Newcastle University), Morven Shuttleworth(University of Dundee), Stefano Aliberti(Mylan (Switzerland)), Oriol Siblia(Universitat de Barcelona), Megan Crichton(University of Dundee), Francesco Blasi(University of Milan), Merete Long(University of Dundee), Arietta Spinou(King's College London)
Cited by 2
Related Papers
European Respiratory Society guidelines for the management of adult bronchiectasis
|European Respiratory Journal|2017|1.3k
Clinical and economic burden of community-acquired pneumonia among adults in Europe
|Thorax|2010|1.1k
Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study
|The Lancet Respiratory Medicine|2020|864
Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections
|Cochrane Database of Systematic Reviews|2017|648
COPD in Never Smokers
|CHEST Journal|2010|517